Sanofi (SNY) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Sanofi’s revenue went from $35.6B in fiscal 2016 to $51.3B in fiscal 2025, growth of about 4.1% a year.
Net income in fiscal 2025 was $9.2B, a net margin of 17.9%; the best year in this period was 2020 with $15.1B.
Over the twelve months to September 30, 2026, revenue was $56.2B and net income $4.6B.
Free cash flow was $8.5B in fiscal 2025 and positive in 7 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.2B | $51.3B | $42.7B | $41.8B | $40.2B | $42.8B | $44.2B | $40.6B | $39.5B | $42.1B | $35.6B |
| Gross profit | — | $39.6B | $32.3B | $32.0B | $30.6B | $30.5B | $30.9B | $28.8B | $27.8B | $29.5B | $25.3B |
| Operating income | — | $7.5B | $7.5B | $7.7B | $10.8B | $9.2B | $17.3B | $3.4B | $5.4B | $7.0B | $6.9B |
| Net income | $4.6B | $9.2B | $5.8B | $6.0B | $8.9B | $7.0B | $15.1B | $3.1B | $4.9B | $10.1B | $5.0B |
| EPS (diluted) | $1.91 | $3.76 | $2.37 | $2.45 | $3.66 | $2.89 | $6.19 | $1.27 | $2.02 | $4.14 | $2.04 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +20.1% | +2.1% | +4.1% | −6.1% | −3.3% | +9.0% | +2.9% | −6.2% | +18.0% | −3.9% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $13.2B | $12.6B | $9.4B | $11.3B | $11.2B | $11.9B | $9.1B | $8.7B | $6.4B | $8.8B | $8.3B |
| Capital spending | -$3.1B | -$4.2B | -$3.3B | -$3.2B | -$2.2B | -$2.3B | -$2.6B | -$2.0B | — | — | — |
| Free cash flow | $9.3B | $8.5B | $6.1B | $8.1B | $9.0B | $9.6B | $6.5B | $6.7B | — | — | — |
| Dividends paid | $5.3B | $5.6B | $4.9B | $4.9B | $4.4B | $4.5B | $4.8B | $4.3B | $4.3B | $4.4B | $4.0B |
| Buybacks | — | $5.9B | $314M | $655M | $530M | $433M | $1.0B | $10M | $1.3B | $2.6B | $3.1B |
| Stock-based pay | — | $368M | $289M | $287M | $250M | $276M | $336M | $283M | $325M | $315M | $254M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $9.0B | $7.7B | $9.6B | $13.6B | $11.4B | $17.1B | $10.6B | $7.9B | $12.4B | $10.8B |
| Debt | — | $22.0B | $16.8B | $18.3B | $20.5B | $23.0B | $27.8B | $27.7B | $28.2B | $18.7B | $19.6B |
| Equity | — | $83.9B | $80.5B | $81.8B | $79.8B | $77.8B | $77.4B | $66.3B | $67.4B | $69.6B | $60.7B |
| Total assets | — | $149.0B | $138.0B | $139.7B | $135.2B | $136.2B | $140.4B | $126.5B | $127.6B | $119.7B | $110.3B |
| Shares (diluted) | 2.41B | 2.44B | 2.44B | 2.44B | 2.44B | 2.44B | 2.44B | 2.44B | 2.44B | 2.44B | 2.44B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 77.2% | 75.7% | 76.7% | 76.2% | 71.3% | 70.0% | 71.0% | 70.3% | 70.2% | 71.0% |
| Operating margin | — | 14.5% | 17.6% | 18.4% | 27.0% | 21.5% | 39.2% | 8.5% | 13.6% | 16.6% | 19.3% |
| Net margin | 8.2% | 17.9% | 13.5% | 14.3% | 22.2% | 16.5% | 34.1% | 7.6% | 12.5% | 24.0% | 13.9% |
| FCF margin | 16.5% | 16.5% | 14.3% | 19.4% | 22.4% | 22.4% | 14.8% | 16.4% | — | — | — |
| ROIC | — | 5.6% | 6.1% | 6.1% | 8.5% | 7.2% | 13.0% | 2.9% | 4.4% | 6.2% | 6.8% |
| ROE | — | 10.9% | 7.2% | 7.3% | 11.2% | 9.1% | 19.5% | 4.7% | 7.3% | 14.5% | 8.2% |
Frequently asked questions
What is Sanofi’s annual revenue?
$51.3B in fiscal 2025 and $56.2B over the twelve months to September 30, 2026.
How much profit does Sanofi make?
Net income was $9.2B in fiscal 2025 (net margin 17.9%).
Is Sanofi’s revenue growing?
Yes: revenue rose 20.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.